3-aza-tricyclo[4.2.1.0(2,5)]nonane | 3927-46-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-aza-tricyclo[4.2.1.0(2,5)]nonane
• 英文别名: 3-Azatricyclo[4.2.1.0^{2,5}]nonane；3-azatricyclo[4.2.1.02,5]nonane
• CAS: 3927-46-6
• 化学式: C₈H₁₃N
• mdl: MFCD19227268
• 分子量: 123.198
• InChiKey: SMYDSCCMFGGJQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  pentacarbonyl((ethoxy)(methyl)carbene)chromium(0) 、 3-aza-tricyclo[4.2.1.0(2,5)]nonane 以 not given 为溶剂， 以73%的产率得到
  参考文献：
  名称：

  Reaction of Aminocarbene Complexes of Chromium with Alkynes. 5. Influence of the Ring Size on the Product Distribution. Formation of Pyrroles from Pyrrolidine and Its Derivative-Substituted Carbene Complexes

  摘要：

  A series of aminocarbene complexes of chromium derived from piperidine (1), hexa- and heptamethyleneimine (4) and (8), pyrrolidine (13a-d, R(1) = Me, H, Ph, thienyl), perhydroindole (21), thiazolidine (24a,b, R(1) = Me, Ph), pyrroline (30a,b), and azetidine (33a-e and 36) have been synthesized and subjected to alkyne insertion reactions. Aminocarbene complex 24a-E has been fully characterized by X-ray structure analysis. Crystal data for 24a-E: C10H9O5NSCr, monoclinic, space group P2(1)/n, a = 8.3011(9) Angstrom, b = 11.949(1) Angstrom, c = 13.101(2) Angstrom, beta = 95.74(1)degrees, V = 1293(1) Angstrom(3), d(calcd) = 1.41 g cm(-3), Z = 4. Whereas complex 1 reacted with diphenylacetylene to give first the ylide complex 2, the thermolysis of which led to the bridgehead lactam 3, complexes 4, and 8 gave directly the expected bridgehead lactams 6 and 11. The structure of 3 has been determined by X-ray diffraction. Crystal data for 3: C27H25ON, monoclinic, space group P2(1)/c, a = 10.080(4) Angstrom, b = 11.727(3) Angstrom, c 18.014(6) Angstrom, beta = 102.40(3)degrees, V = 2080(14) Angstrom(3), d(calcd) = 1.21 g cm(-3), Z = 4. In contrast to 1, 4, and 8, all of the new carbene complexes derived from five-membered cycloamines except 24b gave pyrrole derivatives as the result of the alkyne/CO insertion followed by migration of an alkyl chain from nitrogen to the carbon atom of the inserted carbonyl group and loss of its oxygen atom. The structures of 14a, the Cr(CO)(3) complex of 15a, and 22 could be unambiguously established by X-ray crystallography. Crystal data for 15: C24H21O3NCr, triclinic, space group P1, a = 6.918(1) Angstrom, b = 10.057(1) Angstrom, c = 15.193(2) Angstrom, alpha = 72.410(9)degrees, beta = 84.99(1)degrees, gamma = 84.66(3)degrees, V = 1001(3) Angstrom(3), d(calcd) = 1.40 g cm(-3), Z = 2. For 22: C24H25N, monoclinic, space group P2(1)/n, a = 11.119(3) Angstrom, b = 10.682(2) Angstrom, c = 15.428(3) Angstrom, beta = 102.23(2)degrees, V = 1791(7) Angstrom(3), d(calcd) = 1.21 g cm(-3), Z = 4. Besides these pyrroles, the expected bridgehead lactams 17a-d were isolated from 13a-d together with the lactone complex 18 in the case of 13b. Crystal data for 18: C19H12O5Cr, orthorhombic, space group Pc2(1)/b, a = 10.356(1) Angstrom, b = 12.366(5) Angstrom, c = 12.529(2) Angstrom, V = 1604.4(8) Angstrom(3), d(calcd) = 1.54 g cm(-3), Z = 4. However, 24b gave as the major insertion product the aminofuran 26, and pyrroline-derived carbene complexes 30a,b gave lactams 32a,b and trace amounts of pyrroles 31a,b. Only trace amounts of pyrroles were detected starting from carbene complexes derived from azetidine (33a-e) and 36, which gave mainly the lactams 35a,d and 37. Mechanisms for these new transformations of aminocarbene complexes of chromium based on the behavior of the Stevens-type acyl-stabilized N-ylides will be suggested.

  DOI：

  10.1021/om00006a024

文献信息

• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：Michellys Pierre-Yves

  公开号：US20080176881A1

  公开（公告）日：2008-07-24

  The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

  本发明提供了新型嘧啶和吡啶衍生物及其药物组合物，以及使用这些化合物的方法。例如，本发明的嘧啶和吡啶衍生物可用于治疗、改善或预防对抗无形淋巴瘤激酶（ALK）活性、焦点粘附激酶（FAK）、ζ链相关蛋白激酶70（ZAP-70）、胰岛素样生长因子（IGF-1R）或其组合的疾病。
• Compounds and composition as protein kinase inhibitors
  申请人：IRM LLC

  公开号：EP2311807A1

  公开（公告）日：2011-04-20

  The invention provides novel pyrimidine and pyridine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

  本发明提供了式 (1) 的新型嘧啶和吡啶衍生物 及其药物组合物，以及使用此类化合物的方法。例如，本发明的嘧啶和吡啶衍生物可用于治疗、改善或预防对抑制无性淋巴瘤激酶（ALK）活性、病灶粘附激酶（FAK）、zeta-链相关蛋白激酶 70（ZAP-70）、胰岛素样生长因子（IGF-1R）或其组合有反应的病症。
• Compounds and compositions as protein kinase inhibitors
  申请人：IRM LLC

  公开号：EP2537830A1

  公开（公告）日：2012-12-26

  The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

  本发明提供了式(1)的新型嘧啶衍生物及其药物组合物，以及使用此类化合物的方法。例如，本发明的嘧啶衍生物可用于治疗、改善或预防对抑制无性淋巴瘤激酶（ALK）活性、病灶粘附激酶（FAK）、zeta-链相关蛋白激酶 70（ZAP-70）、胰岛素样生长因子（IGF-1R）或其组合有反应的病症。
• COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP3012249A1

  公开（公告）日：2016-04-27

  The invention provides novel pyrimidine and pyridine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

  本发明提供了式(1)的新型嘧啶和吡啶衍生物及其药物组合物，以及使用此类化合物的方法。例如，本发明的嘧啶和吡啶衍生物可用于治疗、改善或预防对抑制无性淋巴瘤激酶（ALK）活性、病灶粘附激酶（FAK）、zeta-链相关蛋白激酶 70（ZAP-70）、胰岛素样生长因子（IGF-1R）或其组合有反应的病症。
• US8039479B2
  申请人：——

  公开号：US8039479B2

  公开（公告）日：2011-10-18